Traws Pharma (TRAW) Expected to Announce Quarterly Earnings on Monday

Traws Pharma (NASDAQ:TRAW) will likely be posting its quarterly earnings results before the market opens on Monday, April 7th. Analysts expect Traws Pharma to post earnings of ($7.00) per share for the quarter.

Traws Pharma Stock Down 6.6 %

NASDAQ TRAW opened at $2.40 on Monday. Traws Pharma has a 1-year low of $2.02 and a 1-year high of $24.75. The firm has a market capitalization of $8.76 million, a P/E ratio of -0.02 and a beta of 1.42. The firm’s 50 day moving average is $4.73.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.